Pathophysiology and management of saphenous vein graft disease

Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(8):565-572. doi: 10.1080/14779072.2023.2233420.

Abstract

Introduction: The saphenous vein graft (SVG) is the most used conduit in CABG. With standardization of its use as a conduit came an understanding of its accelerated atherosclerosis, known as saphenous vein graft disease (SVGD). Given its extensive use, a review of the pathophysiology and management of SVGD is important as we optimize its use.

Areas covered: For this review, an extensive literature search was completed to identify and examine the evolution of SVG in CABG, mechanisms driving SVGD, and methods developed to prevent and manage it. This includes a review of relevant major papers and trials in this space.

Expert opinion: Eras of evolution in SVG usage in CABG include an experimental era, era of SVG dominance in CABG, and the current era of mixed venous and arterial grafting. As SVGD was studied, the mechanisms behind it became more understood, and prevention and management methods were developed. As advances in surgical techniques and pharmacotherapy continue to reduce occurrence and severity of SVGD, long-term patency of SV grafts continues to improve and remain excellent in optimized settings. With continued innovation and improvement in operative techniques, the SVG conduit is and will remain an important player in the field of coronary bypass.

Keywords: CABG; graft; patency; saphenous; vein.

Publication types

  • Review

MeSH terms

  • Atherosclerosis*
  • Coronary Artery Bypass / adverse effects
  • Coronary Artery Bypass / methods
  • Humans
  • Saphenous Vein* / transplantation
  • Treatment Outcome
  • Vascular Patency